LYSOGENE
Neuilly-sur-seine
About LYSOGENE
Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders . Their mission is to radically improve the health of patients suffering from incurable life threatening conditions. They do this by developing AAV vectors that have demonstrated their effectiveness in safely delivering genetic material to the central nervous system.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $30.3M
- Funding stage: IPO
- Last round: Post-IPO Debt (Dec 2021)
- Ticker: epa:LYS
- Website: lysogene.com
- Phone: +33 1 56 88 52 86
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/lysogene-140497 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.